Azithromycin for the Secondary Prevention of Coronary Heart Disease Events: The WIZARD Study: A Randomized Controlled Trial

JAMA

Volumn 290, Issue 11, 2003, Pages 1459-1466

  O'Connor, Christopher M ^a   Dunne, Michael W ^b   Pfeffer, Marc A ^c   Muhlestein, Joseph B ^d   Yao, Louis ^g   Gupta, Sandeep ^e   Benner, Rebecca J ^b   Fisher, Marian R ^f   Cook, Thomas D ^f  

^a DUKE UNIVERSITY   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN G; PLACEBO; STATINE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY;

ABDOMINAL PAIN; ADULT; ARTICLE; ATHEROGENESIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HAZARD ASSESSMENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SECONDARY PREVENTION; SIDE EFFECT; TREATMENT OUTCOME; BACTERIAL INFECTION; BLOOD; CORONARY ARTERY DISEASE; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; AZITHROMYCIN; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS;

EID: 0141723577     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.11.1459     Document Type: Article

References (27)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
3. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM, Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000;102:2329-2334.
4. Jude B, Agraou B, McFadden EP, et al. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation. 1994;90:1662-1668.
5. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-986.
6. Knoebel E, Vijayagopal P, Figueroa JE II, Martin DH. In vitro infection of smooth muscle cells by Chlamydia pneumoniae. Infect Immun. 1997;65:503-506.
7. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis. 1992;15:757-761.
8. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107-2113.
9. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-2142.
10. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A. 1995;92:6911-6914.
11. Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study. Circulation. 2000;102:2335-2340.
12. Dahlen GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis. 1995;114:165-174.
13. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia, are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest. 1999;103:747-753.
14. Blessing E, Lin TM, Campbell LA, Rosenfeld ME, Lloyd D, Kuo C. Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice. Infect Immun. 2000;68:4765-4768.
15. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35:48-52.
16. Liu L, Hu H, Ji H, Murdin AD, Pierce GN, Zhong G. Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. Mol Cell Biochem. 2000;215:123-128.
17. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633-636.
18. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet. 1997;350:404-407.
19. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation. 2002;105:1298-1303.
20. Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation. 2002;105:1555-1560.
21. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
22. Anderson JL, Muhlestein JB, ACADEMIC (Azithromycin in coronary artery disease: elimination of myocardial infarction with chlamydia). Clin Cardiol. 1998;21:429-431.
23. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation. 2000;102:1755-1760.
24. Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (Weekly Intervention With Zithromax [azithromycin] for Atherosclerosis and Its Related Disorders) trial. J Infect Dis. 2000;181 (suppl 3):S572-S578.
25. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105:15-21.
26. Dunne M. The evolving relationship between Chlamydia pneumoniae and atherosclerosis. Curr Opin Infect Dis. 2000;13:583-591.
27. Jackson LA. Description and status of the Azithromycin and Coronary Events Study (ACES). J Infect Dis. 2000;181 (suppl 3):S579-S581.